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CHROMOSOMAL AND MUTATIONAL ANALYSIS 
OF THE CISPLATIN RESISTANT PHENOTYPE IN NSCLC CELLS 
 
Martin P. Barr, Leah C. Alcock, Raymond L. Stallings, Sinead 
Toomey, Aoife Carr, Bryan T. Hennessy, Derek Richard &                                                                               
Kenneth O‘Byrne 
 
Background:  
Primary and acquired resistance to platinum agents 
such as cisplatin have become a major obstacle in the management 
of lung cancer patients, in particular non-small cell lung cancer 
(NSCLC). The availability of comprehensive genomic data on 
DNA copy number changes in cisplatin resistant NSCLC is limited, 
and little is known about the genes driving this chemoresistant 
phenotype. Detailed molecular portraits through high density 
genomic DNA arrays and genome wide mutation profiles will aid in 
understanding the molecular basis of individual responses to new 
molecular therapies. 
 
Methods:  
A panel of cisplatin resistant (CisR) NSCLC cell lines 
were recently generated and characterised in our laboratory. In 
this study, high resolution array-based comparative genome 
hybridization 
(aCGH) was performed on a panel of five CisR NSCLC 
cell lines to examine DNA copy number gains, losses and 
amplifications. 
Cellular DNA (500ng) and control DNA was differentially 
labelled with Cy3 and Cy5, respectively. Labelled test (4μg) and 
reference DNA were hybridised to a 12-plex 135,000 probe array 
(Roche NimbleGen) for 18 hours in a MAUI hybridisation station 
(BioMicro Systems) at 42°C. Fluorescent intensities were extracted 
and log 2 ratios calculated and normalized using NimbleScan 
Software 
(version 2.4). Chromosomal aberrations were identified using 
the CGH-segMNT algorithm (NimbleScan 2.4). A significance log 
2 ratio threshold of <−0.25 for loss and >0.25 for gain was used to 
identify DNA copy number imbalances. For mutational analysis, 
Sequenom®, a mass-spectrometry-based SNP genotyping 
technology, 
was used to identify mutations in our panel of resistant cell 
lines. Using a literature search and the Catalogue of Somatic 
Mutations 
in Cancer (COSMIC) database, a mutation panel was identified 
for the detection of 547 frequently occurring and potentially 
clinically relevant mutations in 49 cancer-related genes. Some of 
these include KRAS, NRAS, BRAF, PIK3CA, MET, CTNNB1, STK11, 
AKT, and EGFR. Matrix chips were analysed on a Sequenom® 
MassArray MALDI-TOF system. Visual inspection and Sequenom® 
typer software were used to perform genotyping based on mass 
spectra. 
 
Results:  
Using aCGH arrays, a number of gains, losses and amplifications 
of various chromosomes were found across a panel of CisR 
cell lines, relative to corresponding PT cells. The most frequently 
occurring of these chromosomal imbalances included gains, losses 
and homozygous deletions on chromosome 3 (MOR, A549, H1299), 
deletions and amplifications on chromosome 7 (H460, A549, 
H1299) and deletions and gains on chromosome 15 (MOR, A549, 
H1299) and chromosome X (MOR, H460, SKMES-1). Deletions on 
chromosomes 4, 6, 11, 12, 14, and amplification of chromosome 5, 
were also identified among the different CisR cell lines. The collation 
and analysis of data arising from mutation analysis of CisR cells 
using the Sequenom® platform are currently being completed. 
 
 
 
Conclusion:  
High-resolution mapping of chromosomal imbalances 
may offer potential in the identification of genes, including 
oncogenes and tumour suppressor genes, affected by these 
imbalances. 
These findings may further contribute to the delineation 
of the genomic profile of cisplatin resistant lung cancer, and offer 
perspectives for the identification of genes contributing to this 
disease phenotype and in assessing the response to new molecular 
treatments. 
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